
Corporate
Agenus Outlines 2026 Priorities as Zydus Deal Closes and France Expands BOT/BAL Access to Three Tumor Types
7h ago
You're signed outSign in or to get full access.
View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
Research analysts covering AGENUS.